Business15 October, 20252 min read
UK Competition Watchdog Demands Vets Publish Prices and Cap Prescription Costs to End Overcharging
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
The CMA found pet owners pay 16.6% more at large vet groups than independent vets Vets should be required to publish clear price lists and provide upfront cost estimates
5 outlets told this the same way.
UK Veterinary Market Reforms
The UK Competition and Markets Authority (CMA) has proposed extensive provisional reforms to the £6.3bn veterinary market to address overpayments and unclear pricing. These reforms include requiring veterinary practices to publish clear price lists and capping prescription fees. The findings reveal significant price increases and higher charges at large corporate groups.
“The UK’s Competition and Markets Authority (CMA) has proposed major reforms in the veterinary sector after finding that pet owners often overpay for medicines and lack clear pricing information.”
Medicines provided by vets sometimes cost twice as much as online alternatives. Proposed solutions include greater transparency on ownership and treatment costs, easier access to cheaper medicines, and an improved Royal College of Veterinary Surgeons (RCVS) “Find a Vet” comparison tool. Legal enforcement of these reforms is expected by the end of 2026.
Vet Care Costs and Transparency
The watchdog links expensive veterinary care to market consolidation and poor transparency. Large corporate groups now charge on average 16.6% more than independent veterinary practices. Prices have increased by 63% since 2016, which is nearly double the rate of inflation.
Some medicines dispensed by veterinarians cost twice as much as those available online. The CMA also highlights that many pet owners find it difficult to compare prices or obtain written estimates for costly treatments. These pressures have caused some owners to delay or avoid seeking care for their sick animals.
Veterinary Cost Transparency Measures
To curb costs and improve choice, the CMA wants compulsory, upfront price lists and clear disclosure of corporate ownership. They also propose written estimates for treatments over £500 and itemised bills. Measures to make cheaper medicines easier to obtain include mandatory written prescriptions for frequently needed medicines and capping prescription fees at £16.
“The CMA proposes 21 measures, including mandatory publication of full price lists, disclosure of whether a practice is part of a large corporate group, written estimates for treatments over £500, itemised bills, and capped prescription fees at £16.”
Vets would be prompted to inform clients about online savings and issue repeat prescriptions automatically unless owners opt out. The RCVS “Find a Vet” website would be upgraded to include pricing data to enable comparison.
Veterinary Business Regulation Reforms
The CMA also points to regulatory shortcomings in the current oversight framework. This framework dates back to 1966 and does not adequately cover the businesses that own most veterinary practices. To address this gap, the proposals would be established on a legal basis, with full enforcement planned by the end of 2026.
Additional time will be allowed for smaller practices to comply. Notably, the reforms target veterinary businesses rather than individual veterinarians. The aim is to reduce commercial pressure within corporate groups.
Improving Pet Care Costs
For pet owners, the practical effects would be significant: easier price comparisons, written estimates for costly treatments, and clearer routes to cheaper medicines online. CMA evidence shows that owners pay on average 16.6% more at large veterinary groups. Medicines from veterinarians can cost twice as much as those purchased online.
“The CMA highlighted that pet owners pay on average 16.6% more at large veterinary groups than independents, and medicines dispensed by vets can cost twice as much as online alternatives.”
Some owners lack written estimates and even delay or avoid treatment due to costs. These measures aim to rebalance the market and reduce overpayment through transparency and competitive pressure.